Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: IMMU-132 infusion is administered to participants in one arm for the study|DRUG: IMMU-132 plus Carboplatin infusion
Sponsor: Gilead Sciences